Abstract
Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Keywords: Alzheimer's disease, beta-amyloid, tau hyperphosphorylation, stroke, therapeutic strategy.
Current Alzheimer Research
Title:Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Volume: 13 Issue: 3
Author(s): Xian-Le Bu, Shu-Sheng Jiao, Yan Lian and Yan-Jiang Wang
Affiliation:
Keywords: Alzheimer's disease, beta-amyloid, tau hyperphosphorylation, stroke, therapeutic strategy.
Abstract: Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials, however, has prompted questions on whether Aβ is the true cause of AD and a valid therapeutic target. Therefore, current therapeutic targets and intervention strategies must be reconsidered. In addition to Aβ, multiple pathological events such as tau hyperphosphorylation, oxidative stress and neuroinflammation are involved in the disease pathogenesis and cause cross-talk between these pathological pathways, which synergistically drive disease progression. Increasing evidence also reveals that the pathogenesis varies at different stages of the disease. Therefore, targeting Aβ alone at all stages of the disease would not be sufficient to halt or reverse disease progression. In the light of the pathophysiologic similarities between the development of ischemic stroke and AD, we can formulate management strategies for AD from the successful practice of ischemic stroke management, namely the tertiary prevention strategy. These new perspectives of tertiary prevention target both Aβ and different pathological pathways of AD pathogenesis at different stages of the disease, and may represent a promising avenue for the effective prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Bu Xian-Le, Jiao Shu-Sheng, Lian Yan and Wang Yan-Jiang, Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151215110114
DOI https://dx.doi.org/10.2174/1567205013666151215110114 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Xanthine Oxidase by Natural Products as a Therapeutic Approach for Mental Disorders
Current Pharmaceutical Design Snapshots of Protein Folding Problem: Implications of Folding and Misfolding Studies
Protein & Peptide Letters Erythrocyte Amyloid Beta Peptide Isoform Distributions in Alzheimer and Mild Cognitive Impairment
Current Alzheimer Research Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Stroke Suggests Increased Risk of Dementia
Current Alzheimer Research Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery Predicting Stability of Mild Cognitive Impairment (MCI): Findings of a Community Based Sample
Current Alzheimer Research Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
Current Alzheimer Research A Surgical Opinion on Hyperalgesia/Nociception, Inflammatory/Neurogenic Pain and Anti-inflammatory Responses and Drug Interventions Revisited: Current Breakthroughs and Views
Current Immunology Reviews (Discontinued) Diagnosis of Mild Cognitive Impairment Using Cognitive Tasks: A Functional Near-Infrared Spectroscopy Study
Current Alzheimer Research Nanotechnology for Alzheimer Disease
Current Alzheimer Research Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
CNS & Neurological Disorders - Drug Targets Fluoxetine Improves Behavioral Performance by Suppressing the Production of Soluble β-Amyloid in APP/PS1 Mice
Current Alzheimer Research Preface
Current Medicinal Chemistry - Central Nervous System Agents Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) Preface: Highlights of Recent Progress in Alzheimers Disease Research [ Hot Topics in Alzheimers Disease Research (Guest Editor: Debomoy K. Lahiri)]
Current Drug Targets